“…MK‐467 is a peripherally acting α 2 ‐adrenoceptor antagonist that poorly penetrates mammalian central nervous tissues; its α 2 ‐ vs. ‐α 1 selectivity ratio is approximately 105:1 (Clineschmidt et al., ). The ability of MK‐467 to attenuate the adverse haemodynamic influences attributed to α 2 ‐agonists has been reported in several species, such as dogs (Enouri, Kerr, McDonell, O'Sullivan, & Neto, ; Honkavaara, Restitutti, Raekallio, Kuusela, & Vainio, ; Pagel et al., ; Rolfe, Kerr, & McDonell, ), horses (Bryant et al., ; Vainionpää et al., ; de Vries et al., ), cats (Honkavaara, Pypendop, & Ilkiw, 2017; Pypendop, Honkavaara, & Ilkiw, ) and sheep (Bryant et al., ; Raekallio et al., ). Furthermore, MK‐467 had no substantial effect on the intensity of sedation induced by medetomidine or dexmedetomidine (Restitutti, Honkavaara, Raekallio, Kuusela, & Vainio, ; Rolfe et al., ).…”